Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 in Age-related Macular Degeneration
NCT04151212Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAT5906 in exudative macular degeneration, sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 2 weeks, Maximum tolerated dose and 5 more. Started Oct 2018; status: completed.
02
Drugs
BAT5906
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT04151212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151212.